Niyati Nadkarni, MD
Gynecologic Oncology · Omaha, NENPI 1275749129
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $656 and has fallen 56.8% since, to $284 in 2025.
Across 27 payments — averaging $67.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$248
- AstraZeneca$247
- Eisai Inc.$204
- Johnson & Johnson$196
- GSK$166
- BD$158
- plus $615 from 8 others
What the payments were for
- Food & beverage$1,834100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $248 |
| AstraZeneca | 2 | $247 |
| Eisai Inc. | 5 | $204 |
| Johnson & Johnson | 5 | $196 |
| GSK | 3 | $166 |
| BD | 1 | $158 |
| Intuitive Surgical | 1 | $148 |
| Genentech USA, Inc. | 1 | $125 |
| Clovis Oncology, Inc. | 1 | $96 |
| Baxter Healthcare | 1 | $91 |
| Myriad Genetic Laboratories, Inc. | 1 | $90 |
| Conmed Corporation | 1 | $29 |
| Pfizer | 1 | $21 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$247
- ARISTA AH FLEXITIP$158
- Da Vinci Surgical System$148
- Elahere$125
- Avastin$125
- JEMPERLI$120
- LENVIMA$117
- VISTASEAL$114
How this compares
Too few gynecologic oncology providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 21 | $1,272 |
| Letrozole | 15 | $475 |
| Megestrol Acetate | 13 | $361 |
| Ondansetron Hcl | 15 | $105 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Omaha
- David CrotzerOmaha$70K
- Steven RemmengaOmaha$4K
- Brent TierneyOmaha$1K
- Kerry RodabaughOmaha$411
- Robin Farias-EisnerOmaha$52
- Murray CaseyOmaha$37
- Kathryn KennedyLincoln$3K
- Peter MorrisLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.